iCLAS™ for Persistent Atrial Fibrillation
The primary objective of this study is to evaluate the safety and efficacy of the Adagio AF Cryoablation System (iCLAS™) in the ablation treatment of symptomatic, persistent atrial fibrillation (PsAF).
- Male or female between the ages of 18-80 years
- Currently scheduled for an ablation of symptomatic PsAF defined as continuous AF that is sustained > 7-days and ≤ 12-months.
- Refractory to at least one class I or III AAD.
- Willingness, ability and commitment to participate in baseline and follow-up evaluations for the full length of the study.